Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: BMS is a global biopharmaceutical company operating in a single segment focused on oncology, hematology, immunology, cardiovascular, and neuroscience. The company's strategy combines large-scale pharmaceutical resources with biotech innovation. In 2024, BMS completed significant acquisitions of Karuna (neuroscience), RayzeBio (radiopharmaceuticals), and Mirati (oncology) to expand its pipeline and commercial portfolio.
Key Financial Metrics
| Metric | 2024 | 2023 | Change |
|---|---|---|---|
| Total Revenues | $48.3 billion | $45.0 billion | +7% |
| Net (Loss)/Earnings (GAAP) | $(8.9) billion | $8.0 billion | N/A |
| Diluted EPS (GAAP) | $(4.41) | $3.86 | $(8.27) |
| Diluted EPS (Non-GAAP) | $1.15 | $7.51 | $(6.36) |
| Operating Cash Flow | $15.2 billion | $13.9 billion | +$1.3 billion |
| Net Debt Position | $(38.5) billion | $(27.1) billion | Increased Debt |
| Research & Development (R&D) | $11.2 billion | $9.3 billion | +20% |
| Acquired IPRD Expenses | $13.4 billion | $0.9 billion | >200% |
Note: GAAP results include a one-time, non-deductible $12.1 billion charge for the Karuna asset acquisition and $1.8 billion in intangible asset impairments.
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 7% to $48.3 billion. Growth was driven by the Growth Portfolio (up 17%) and Eliquis (up 9%), partially offset by generic erosion in the Legacy Portfolio (flat).
- Profitability Impact: GAAP net loss of $8.9 billion in 2024 compared to net earnings of $8.0 billion in 2023. This swing was primarily due to the $12.1 billion non-cash Acquired IPRD charge from the Karuna acquisition and $2.9 billion in total impairment charges (intangible assets and IPRD).
- Expense Increases: R&D expenses rose 20% to $11.2 billion due to higher drug development costs and acquisition-related charges. Cost of products sold increased 31% largely due to impairment charges and higher royalties.
- Debt Levels: Net debt increased by $11.4 billion to $38.5 billion, driven by the issuance of $13.0 billion in Senior Unsecured Notes to fund the Karuna and RayzeBio acquisitions.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- Strategic Productivity: BMS expanded its strategic productivity initiative, now targeting approximately $2.0 billion in additional annual cost savings by the end of 2027, to be reinvested in innovation.
- Legacy Portfolio Erosion: Management expects continued generic erosion in 2025, primarily affecting Revlimid, Sprycel, and Pomalyst (outside the U.S.).
- Pipeline Milestones: The company anticipates 10 or more new medicines and multiple additional indications over the next five years, with key readouts expected in 2025/2026 for assets like Opdivo, Opdualag, and Cobenfy.
Key Risks and Contingencies:
- IRA Impact: The Inflation Reduction Act (IRA) poses significant pricing risks. The HHS selected Eliquis for price negotiation effective 2026 and Pomalyst for 2027. This could accelerate revenue erosion prior to patent expiry.
- Patent Expirations: Key products face exclusivity loss. Revlimid volume-limited licenses in the U.S. end January 2026. Eliquis faces generic entry in the EU and potential U.S. entry in 2028.
- Legal Proceedings: Ongoing litigation includes patent challenges for Eliquis in Europe, securities litigation related to the Celgene acquisition (CVRs), and pricing/promotional practices disputes.
- Acquisition Integration: Risks associated with integrating Karuna, RayzeBio, and Mirati, including potential underperformance or failure to realize synergies.
Investor Verification Checklist
- Non-GAAP Reconciliation: Verify the specific adjustments made to reconcile GAAP loss to Non-GAAP earnings, particularly the treatment of the $12.1 billion Karuna IPRD charge and impairment charges.
- IRA Pricing Exposure: Assess the specific financial modeling used to estimate the impact of the IRA price negotiations on Eliquis (2026) and Pomalyst (2027).
- Legacy Portfolio Run-Rate: Confirm the projected revenue decline rates for Revlimid, Sprycel, and Pomalyst in 2025 given the expiration of volume-limited licenses and generic entry.
- Debt Service Capacity: Review the company's ability to service the increased debt load ($38.5 billion net debt) while maintaining R&D investment and dividend payments ($0.60/share quarterly).
- Intangible Asset Valuation: Scrutinize the assumptions behind the $2.9 billion in impairment charges (Augtyro, Abecma, Inrebic, and IPRD) to understand if further write-downs are likely.